https://www.aigom.it/wp-content/uploads/2025/04/Screenshot-2025-04-11-100128-2.png428300Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-11 08:12:362025-04-11 08:17:3916 GIUGNO 2025-AIGOM LE NOVITA’ DA CHICAGO 2025: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA
https://www.aigom.it/wp-content/uploads/2025/04/Screenshot-2025-04-15-160435.png1017750Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 14:04:572025-04-15 14:20:51NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 11-SABATO 12 APRILE 2025
https://www.aigom.it/wp-content/uploads/2025/04/10aprile.png980700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 13:59:492025-04-15 14:19:52NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE GIOVEDI 10 APRILE 2025
https://www.aigom.it/wp-content/uploads/2025/04/8-APRILE.png1301960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 07:56:242025-04-08 07:56:24CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2025/04/1aprile.png15431073Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-01 08:32:102025-04-01 08:32:10FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/03/2aprile1.png831600Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:40:272025-03-25 09:40:272 APRILE 2025-NUTRIZIONE E ONCOLOGIA: UN DIALOGO TRA RICERCA DI BASE E CLINICA
https://www.aigom.it/wp-content/uploads/2025/03/25.3.png1215960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:16:212025-03-25 09:16:21PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).
https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
